News

Gates Foundation grants Evotec $2.9M for drug safety screening

What's the deal? Evotec has received a $2.9 million grant from the Bill & Melinda Gates Foundation to extend its work on early drug safety testing using human stem cell technology. The three-year award funds an in-vitro, high-throughput platform to spot teratogenicity — risks to fetal development — in drug candidates.

What's the endgame? The grant builds on Evotec's 2023 safety initiative and its New Approach Methodologies (NAMs), which predict developmental risks earlier in the pipeline. The aim: help global-health researchers flag problems before costly clinical testing.

Why now? The award extends the Gates Foundation's recent work with the German company. In April 2026, two grants totaling $9.9 million supported Evotec's tuberculosis drug discovery, following earlier TB funding.

What's the context? "Identifying safety concerns early is critical," said chief scientific officer Joanna Holbrook, framing the platform as a way to make informed calls on drug candidates. The system has screened more than 5,000 compounds and could reduce reliance on animal testing.

The grant is targeted research support, not a material corporate financing. Evotec reported declining nine-month 2026 revenue and an operating cash outflow of €155 million.

The signal: At $2.9 million, the award sits in the 95th percentile for grant rounds to AI companies in Germany — modest in absolute terms, but notable as sustained institutional backing for human-cell screening over animal models.

Read more: webdisclosure.com

Image credit: Evotec

More top stories